BOCA RATON, Fla.--(BUSINESS WIRE)--Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy, HIV and Multiple Sclerosis, has announced today that its wholly-owned drug discovery subsidiary, ReceptoPharm, will provide RPI-78M under compassionate release to patients previously enrolled in the Phase IIb/IIIa clinical study of Adrenomyeloneuropathy (AMN). RPI-78M is ReceptoPharm’s leading drug candidate for treating neurological and autoimmune disorders.
